Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12 04:00PM ET
17.50
Dollar change
-1.37
Percentage change
-7.26
%
Index- P/E- EPS (ttm)-2.26 Insider Own57.69% Shs Outstand2.17M Perf Week-23.75%
Market Cap45.60M Forward P/E- EPS next Y- Insider Trans18.74% Shs Float1.10M Perf Month443.48%
Income-4.01M PEG- EPS next Q- Inst Own1.41% Short Float8.53% Perf Quarter993.75%
Sales0.50M P/S91.20 EPS this Y- Inst Trans-5.84% Short Ratio0.06 Perf Half Y944.15%
Book/sh0.71 P/B24.61 EPS next Y- ROA-33.98% Short Interest0.09M Perf Year446.88%
Cash/sh0.13 P/C134.12 EPS next 5Y- ROE-132.62% 52W Range1.44 - 36.00 Perf YTD503.14%
Dividend Est.- P/FCF- EPS past 5Y33.58% ROI-57.44% 52W High-51.39% Beta3.71
Dividend TTM- Quick Ratio0.71 Sales past 5Y1609.08% Gross Margin-61.80% 52W Low1115.28% ATR (14)4.69
Dividend Ex-Date- Current Ratio0.71 EPS Y/Y TTM-126.39% Oper. Margin-1000.60% RSI (14)52.66 Volatility23.28% 37.78%
Employees6 Debt/Eq3.98 Sales Y/Y TTM-97.70% Profit Margin-801.40% Recom3.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq3.53 EPS Q/Q81.09% Payout- Rel Volume0.05 Prev Close18.87
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume1.55M Price17.50
SMA20-0.84% SMA50101.76% SMA200337.51% Trades Volume82,356 Change-7.26%
Date Action Analyst Rating Change Price Target Change
Dec-13-21Downgrade Chardan Capital Markets Buy → Neutral $2.25 → $0.40
Dec-18-20Initiated BMO Capital Markets Outperform $6
Nov-20-19Initiated Guggenheim Buy $9
Nov-14-24 04:01PM
Sep-18-24 04:01PM
Sep-09-24 06:53PM
Aug-26-24 09:08AM
Aug-19-24 10:31AM
10:31AM Loading…
Aug-15-24 10:31AM
Aug-13-24 04:01PM
Aug-08-24 04:27PM
Aug-02-24 07:34AM
Aug-01-24 04:01PM
Jul-26-24 07:36AM
Jun-17-24 09:53PM
04:01PM
Jun-06-24 09:52PM
04:01PM
07:39AM Loading…
May-29-24 07:39AM
May-23-24 04:01PM
May-16-24 09:52PM
04:08PM
Apr-22-24 04:01PM
Feb-06-24 07:05AM
Feb-05-24 04:01PM
Dec-08-23 08:40AM
Nov-28-23 04:01PM
Aug-23-23 09:48AM
Aug-11-23 04:01PM
Jul-14-23 04:01PM
May-26-23 04:01PM
May-19-23 04:01PM
May-04-23 04:01PM
07:00AM Loading…
Apr-27-23 07:00AM
Mar-27-23 04:01PM
Feb-24-23 05:10PM
Dec-14-22 05:00AM
Nov-14-22 04:01PM
Sep-26-22 04:01PM
Sep-01-22 07:00AM
Aug-15-22 04:01PM
Jul-20-22 04:01PM
Jun-29-22 12:00PM
May-27-22 04:01PM
May-17-22 07:00AM
May-16-22 04:01PM
May-10-22 07:21PM
May-09-22 07:00AM
Mar-25-22 04:15PM
Feb-04-22 11:25AM
07:00AM
Jan-05-22 01:38PM
Dec-31-21 07:07PM
06:02PM
02:53PM
01:15PM
Dec-30-21 05:57PM
03:31PM
10:00AM
Dec-29-21 11:46PM
05:57PM
04:30PM
10:45AM
Dec-28-21 05:57PM
02:50PM
10:00AM
Dec-27-21 03:16PM
11:00AM
Dec-26-21 08:32AM
Dec-24-21 06:13PM
01:56PM
10:40AM
Dec-23-21 08:38PM
09:30AM
Dec-22-21 06:22PM
05:59PM
04:50PM
02:32PM
11:00AM
10:00AM
Dec-21-21 05:54PM
04:08PM
11:00AM
09:30AM
07:38AM
Dec-20-21 05:47PM
03:49PM
11:00AM
11:00AM
10:00AM
Dec-19-21 09:00PM
08:32AM
Dec-17-21 06:13PM
05:00PM
01:40PM
12:32PM
09:45AM
Dec-16-21 03:50PM
03:00PM
11:00AM
11:00AM
12:49AM
Dec-15-21 05:59PM
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DGP Co., Ltd.10% OwnerSep 12 '24Buy3.00237,223711,669849,223Sep 16 09:41 PM
DGP Co., Ltd.10% OwnerFeb 29 '24Sale1.323,400,0004,488,0000Mar 04 06:36 PM